Overview
Alopecia of pregnancy, also known as telogen effluvium of pregnancy, is a common cause of temporary hair loss that occurs during or after pregnancy. It is characterized by diffuse shedding of hair, typically starting a few months postpartum.Diagnosis
Diagnosis is primarily clinical, based on patient history and physical examination.
Key features include a sudden onset of diffuse hair shedding, often noted by the patient several months after delivery.
Examination may reveal increased shedding upon gentle traction.Management
Reassurance and patient education regarding the temporary nature of the hair loss are important.
Nutritional assessment and supplementation (e.g., iron, vitamins) may be considered if deficiencies are identified.
Topical minoxidil is sometimes used, though its safety and efficacy specifically for postpartum alopecia are not well-established in large trials.Special Populations
Pregnancy
Alopecia of pregnancy is a common, self-limiting condition.
Most cases resolve spontaneously within 6 to 12 months postpartum without specific treatment.
The safety of biological agents like dupilumab during pregnancy has been reviewed, with current evidence suggesting it is probably safe for atopic dermatitis, showing no significant increase in miscarriage or congenital malformations compared to the general population 1. However, this abstract focuses on atopic dermatitis and not alopecia.Key Recommendations
Reassurance and education regarding the typically self-limiting nature of postpartum alopecia are recommended. (Evidence: Expert opinion)
Nutritional deficiencies should be assessed and addressed if identified. (Evidence: Expert opinion)
The safety of dupilumab for atopic dermatitis during pregnancy is suggested by current evidence, with no significant increase in the risk of miscarriage or congenital malformations 1. (Evidence: Moderate)References
1 Sánchez-García V, De-Miguel-Balsa E, Ramos-Rincón JM, Belinchón-Romero I. Safety of Dupilumab Therapy for Atopic Dermatitis during Pregnancy: A Systematic Review and Meta-analysis. Acta dermato-venereologica 2025. link